The Pathophysiology, Diagnosis and Some Management Approaches of Alzheimer’s Disease: An Overview

Alzheimer’s disease is the greatest mutual cause of dementia globally, with the occurrence ongoing to grow in part because of the aging world populace. This neurodegenerative disease process is categorized characteristically by 2 mark pathologies: β-amyloid plaque deposition and neurofibrillary masses of hyperphosphorylated tau. Diagnosis is grounded on biomarkers restrained in vivo even beforehand the onset of clinical dementia symptoms. No solitary biomarker can by itself properly diagnose AD. A grouping of biomarkers measured over imaging and cerebrospinal fluid produces well diagnostic precision. However amyloid PET imaging and CSF heights of amyloid and tau deposits are progressively used in AD clinical trials to increase diagnostic declaration in enrolled subjects,monotonous use of these biomarkers in clinical locations is still early because of the risk of overdiagnosis, increased cost and/or invasiveness of the valuation method. Treatment is currently targeted toward symptomatic therapy, in which some of the treatment approaches are mentioned in this review, though the more research and trials are underway who’s objective is to deduce the production and overall burden of pathology within the brain. Now, we deliberate recent developments in our understanding of the clinical assessment and treatment of Alzheimer’s disease, with updates concerning clinical trials still in progress.